Form 8-K - Current report:
SEC Accession No. 0001520138-21-000322
Filing Date
2021-06-11
Accepted
2021-06-11 09:00:47
Documents
14
Period of Report
2021-06-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT bivi-20210610_8k.htm   iXBRL 8-K 39368
2 EXHIBIT 10.1 bivi-20210610_8kex10z1.htm EX-10.1 96915
3 EXHIBIT 99.1 bivi-20210610_8kex99z1.htm EX-99.1 9380
  Complete submission text file 0001520138-21-000322.txt   345880

Data Files

Seq Description Document Type Size
4 XBRL LABEL FILE bivi-20210610_lab.xml EX-101.LAB 34238
5 XBRL PRESENTATION FILE bivi-20210610_pre.xml EX-101.PRE 22371
6 XBRL SCHEMA FILE bivi-20210610.xsd EX-101.SCH 3102
7 EXTRACTED XBRL INSTANCE DOCUMENT bivi-20210610_8k_htm.xml XML 3590
Mailing Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404
Business Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404 310-444-4300
BIOVIE INC. (Filer) CIK: 0001580149 (see all company filings)

EIN.: 462510769 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39015 | Film No.: 211010064
SIC: 2834 Pharmaceutical Preparations